A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5570 participants.
Also called NCT01709305
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 5,570 participants
- Sponsor
- Registry
-
NCT01709305
-
- Other papers using this trial's data
- Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01709305. Randomized; no masking; primary purpose treatment. Start 2012-11-08 (actual); primary completion 2015-04-17 (actual). Results posted on 2016-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Acarbose
- Intervention (Drug)
- Repaglinide
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Gliclazide
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01709305- Content hash
220ad1ba3c4378e19a8800caedd1310fd0fe6b0b36dbcdee45d5f39c43e3aeec